The 2019PGDISposition statement on transfer of mosaic embryos within a context of new information on PGT-A

Background A recently published Position Statement (PS) by thePreimplantation Genetics Diagnosis International Society (PGDIS)regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF) contained inaccuracies and misrepresentations. Because opinions issued by thePGDIShave since 2016 determined worldwide IVF practice, corrections appear of importance. Methods TheInternational Do No Harm Group in IVF (IDNHG-IVF)is a spontaneously coalesced body of international investigators, concerned with increasing utilization of add-ons to IVF. It is responsible for the presented consensus statement, which as a final document was reached after review of the pertinent literature and again revised after the recent publication of the STAR trial and related commentaries. Results In contrast to the PGDIA-PS, we recommend restrictions to the increasing, and by IVF centers now often even mandated, utilization of PGT-A in IVF cycles. While PGT-A has been proposed as a tool for achieving enhanced singleton livebirth outcomes through embryo selection, continued false-positive rates and increasing evidence for embryonic self-correction downstream from the testing stage, has ledIDNHG-IVFto conclude that currently available data are insufficient to impose overreaching recommendations for PGT-A utilization. Discussion Here presented consensus offers an alternative to the 2019PGDISposition statement regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF). Mindful of what appears to offer best outcomes for patients, and in full consideration of patient autonomy, here presented opinion is based on best available evidence, with the goal of improving safety and efficacy of IVF and minimizing wastage of embryos with potential for healthy births. Conclusions As thePGDISnever suggested restrictions on clinical utilization of PGT-A in IVF, here presented rebuttal represents an act of self-regulation by parts of the IVF community in attempts to control increasing utilization of different unproven recent add-ons to IVF.